BRAF and colorectal cancer: V600EBRAF mutation is detected in 8–12% of colorectal cancer (CRC) patients, accounting for more than 90% of CRC BRAF mutations.1 It is an independent negative prognostic factor in CRC across all stages.2,3 Furthermore, a recent consensus work identified BRAF mutational status as one of the top five fundamental stratification characteristics in the initial evaluation of metastatic CRC (mCRC) patients, together with RAS mutations, patients’ performance status, primary tumour sidedness and presence of liver-limited disease.4